Design Therapeutics, Inc. announced the initiation of a Phase 1 clinical trial for its gene-targeted treatment DT-216P2 in healthy volunteers, with patient dosing for Friedreich Ataxia (FA) set to ...

Clinical trials are losing participants. Patient-first design and decentralized models can help fix the dropout problem.

– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and ...

Written agreement from FDA for single-arm, open-label, baseline-controlled registrational trial evaluating composite primary endpoint of improvement in CGI-I and gain of developmental milestone/skill ...

TORONTO, April 3, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming ...

Felicione is an independent clinical research scientist and principal investigator. Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising ...

This Collection supports and amplifies research related to SDG 3: Good Health & Wellbeing. Developing disease-modifying therapies for Parkinson’s disease (PD) is one of the most pressing, plausible, ...

Different groups of people—men, women, children, and people of different races or ethnic backgrounds—respond differently to different drugs. Clinical trials are supposed to drive advances in medicine ...